Arlevert tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arlevert tablets

hennig arzneimittel gmbh & co. kg - cinnarizine; dimenhydrinate - oral tablet - 20mg ; 40mg

Elmiron European Union - English - EMA (European Medicines Agency)

elmiron

bene-arzneimittel gmbh - pentosan polysulfate sodium - cystitis, interstitial - urologicals - elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.,

LAIF 600 Israel - English - Ministry of Health

laif 600

bayer israel ltd - hypericum perforatum - film coated tablets - hypericum perforatum 612 mg - symptoms of mild to moderate depression. treatment is recommended for up to 24 weeks.

Selesyn 100 micrograms/2 ml, oral solution (50 micrograms/ml) Ireland - English - HPRA (Health Products Regulatory Authority)

selesyn 100 micrograms/2 ml, oral solution (50 micrograms/ml)

biosyn arzneimittel gmbh - selenium - oral solution - 100 µg/2ml - selenium; sodium selenite

Selesyn 500 micrograms/10 ml, oral solution (50 micrograms/ml) Ireland - English - HPRA (Health Products Regulatory Authority)

selesyn 500 micrograms/10 ml, oral solution (50 micrograms/ml)

biosyn arzneimittel gmbh - selenium - oral solution - 500 microgram(s) - selenium; sodium selenite

Vesanoid 10 mg soft capsules Ireland - English - HPRA (Health Products Regulatory Authority)

vesanoid 10 mg soft capsules

cheplapharm arzneimittel gmbh - tretinoin - capsule, soft - 10 milligram(s) - cytostatic-differentiating agent

Xenical European Union - English - EMA (European Medicines Agency)

xenical

cheplapharm arzneimittel gmbh - orlistat - obesity - antiobesity preparations, excl. diet products - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.